ABVC BioPharma, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ABVC Nasdaq 2830 www.abvcpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ABVC BioPharma, Inc.

ABVC BioPharma and AiBtl BioPharma's Worldwide Business Development Team Participate in the 43rd Annual J.P. Morgan Healthcare Conference - Jan 16th, 2025 1:30 pm
ABVC BioPharma s ADHD and MDD Drug Polygala Tenuifolia a Natural Wonder With Potential of Transforming Mental Health Treatment of More Than 30 Billion Market - Jan 15th, 2025 1:30 pm
AiBtl BioPharma Strengthens Partnership With ABVC BioPharma, Paying $150,000 in Licensing Fees - Jan 14th, 2025 1:30 pm
ABVC BioPharma, Inc. Granted Additional 180-Day Grace Period to Regain Compliance With Nasdaq Bid Price Requirement - Jan 13th, 2025 2:00 pm
ABVC BioPharma and ForSeeCon: An Update on Alliance's Ophthalmology-Related Products - Jan 7th, 2025 1:30 pm
ABVC BioPharma Secures an Additional Patent for ADHD Treatment, in Addition to the Granted U.S. and Australian Patents, Moving Forward to the Global Patent Map of $32.14 Billion Potential Market - Jan 2nd, 2025 2:00 pm
ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21 - Dec 19th, 2024 1:30 pm
ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners - Dec 11th, 2024 11:30 am
ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones - Nov 14th, 2024 2:00 pm
ABVC BioPharma Receives $50,000 in Incremental Licensing Fees, Boosting Total Payments to $346,000 From Its Three Strategic Partners - Oct 22nd, 2024 12:45 pm
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements - Aug 15th, 2024 11:30 am
ABVC and AiBtl to Launch a New Clinical Study on Depression in Cancer Patients Using AI - Jul 9th, 2024 11:16 am
ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals - Jul 2nd, 2024 1:00 pm
ABVC BioPharma Awarded ADHD Treatment Patent in Australia, a Potential $32 Billion Market - Jun 25th, 2024 1:00 pm
ABVC BioPharma Receives First Cash Licensing Payment Anticipating $5 Million in Revenue - Jun 12th, 2024 1:20 pm
Immunity Boosting Combination Therapy for Myelodysplastic Syndrome (pre-Leukemia) Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Eligible to Receive Aggregate Income of $13.75M and Royalties of up to $12.50M - May 24th, 2024 1:00 pm
ABVC CEO's Letter to Shareholders: The Future Looks Bright for ABVC; Anticipating Cash Incomes Totaling up to $24M - May 22nd, 2024 1:00 pm
Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M - May 15th, 2024 1:25 pm
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M - May 9th, 2024 1:35 pm
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share - Apr 18th, 2024 1:25 pm